<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To assess the relationship between osteoprotegerin (OPG) and cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo>, and the pathobiological mechanisms contributing to the association, in <z:hpo ids='HP_0011009'>acute</z:hpo> coronary syndromes (ACS) </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN: Prospective observational </plain></SENT>
<SENT sid="2" pm="."><plain>SETTING: Biomarker substudy of MERLIN-TIMI 36, a randomised, placebo controlled trial of ranolazine in non-ST elevation (NSTE)-ACS </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS: 4463 patients with NSTE-ACS </plain></SENT>
<SENT sid="4" pm="."><plain>INTERVENTIONS: Ranolazine or placebo </plain></SENT>
<SENT sid="5" pm="."><plain>MAIN OUTCOME MEASURES: Incidence of cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo> (CV <z:hpo ids='HP_0011420'>death</z:hpo>); additionally, <z:hpo ids='HP_0001635'>heart failure</z:hpo> (HF), <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo>, in-hospital <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>, severe recurrent <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> or recurrent <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (MI) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: During a median follow-up of 341 days, 208 patients died of cardiovascular causes </plain></SENT>
<SENT sid="7" pm="."><plain>The OPG baseline concentration was strongly associated with both 30 day and 1 year incidence of CV <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>After adjustment for conventional risk markers, OPG concentrations (log transformed) remained a significant predictor of CV <z:hpo ids='HP_0011420'>death</z:hpo> by 30 days (HR (95% CI) 2.32 (1.30 to 4.17); p=0.005) and by 1 year (HR 1.85 (1.33 to 2.59); p&lt;0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>Baseline levels of OPG were also an independent predictor of new or worsening HF at 30 days (HR 2.25 (1.38 to 3.69); p=0.001) and 1 year (HR 1.81 (1.26 to 2.58) p=0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>By univariable analysis, higher OPG was associated with both early ischaemic and arrhythmic events </plain></SENT>
<SENT sid="11" pm="."><plain>Although OPG levels were associated with recurrent MI within 12 months, this association was attenuated and no longer significant after multivariable adjustment </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: OPG is independently associated with 30 day and 1 year risk of cardiovascular mortality and HF development after NSTE-ACS </plain></SENT>
<SENT sid="13" pm="."><plain>As no independent relationship between OPG levels and recurrent <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> or MI was observed, myocardial dysfunction may be a more important stimulus for OPG production than <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> in ACS </plain></SENT>
</text></document>